Immune booster: Off-the-Shelf cell therapy takes on tough lymphoma
NCT ID NCT04673617
First seen Apr 15, 2026 · Last updated May 18, 2026 · Updated 8 times
Summary
This study tested a new treatment called AB-101, made from natural killer (NK) cells, for people with a type of blood cancer called non-Hodgkin lymphoma that had come back or stopped responding to other treatments. The treatment was given alone or combined with other drugs. The goal was to see if it was safe and could shrink tumors. The study included 45 adults and has been completed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-HODGKIN LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Artiva Clinical Trial Site
Birmingham, Alabama, 35249, United States
-
Artiva Clinical Trial Site
Tucson, Arizona, 85719, United States
-
Artiva Clinical Trial Site
Orange, California, 92868, United States
-
Artiva Clinical Trial Site
San Diego, California, 92093, United States
-
Artiva Clinical Trial Site
Gainesville, Florida, 32608, United States
-
Artiva Clinical Trial Site
Atlanta, Georgia, 30342, United States
-
Artiva Clinical Trial Site
Chicago, Illinois, 60612, United States
-
Artiva Clinical Trial Site
Iowa City, Iowa, 52242, United States
-
Artiva Clinical Trial Site
Wichita, Kansas, 67214, United States
-
Artiva Clinical Trial Site
Louisville, Kentucky, 40241, United States
-
Artiva Clinical Trial Site
Detroit, Michigan, 48201, United States
-
Artiva Clinical Trial Site
Lake Success, New York, 11042, United States
-
Artiva Clinical Trial Site
New York, New York, 11021, United States
-
Artiva Clinical Trial Site
Columbus, Ohio, 43214, United States
-
Artiva Clinical Trial Site
Portland, Oregon, 97239, United States
-
Artiva Clinical Trial Site
Philadelphia, Pennsylvania, 19107, United States
-
Artiva Clinical Trial Site
Philadelphia, Pennsylvania, 19111, United States
-
Artiva Clinical Trial Site
Providence, Rhode Island, 02903, United States
-
Artiva Clinical Trial Site
Dallas, Texas, 75246, United States
-
Artiva Clinical Trial Site
Salt Lake City, Utah, 84112, United States
-
Artiva Clinical Trial Site
Richmond, Virginia, 23298, United States
Conditions
Explore the condition pages connected to this study.